Novartis AG ADR

This shortlist of high-quality companies with predictable cash flows and modest leverage are well-equipped for today’s market uncertainty.

These stocks are among the top holdings of some of our favorite investment managers.

Recent results from some of the most undervalued large drugmakers we cover.

We think these wide-moat companies are poised to experience meaningful economic benefits in the future.

Sector director Damien Conover shares his key takeaways from Johnson & Johnson, Novartis, Glaxo, and Bristol Myers Squibb's reports.

Gold-rated Dodge & Cox Stock proves that low-cost active management can still add value.

The fund looks promising, but there's no reason to rush to invest during the subscription period.

Innovation and M&A may drive these firms' fortunes.

Morningstar experts discuss patient benefits, costs, and planning for healthcare amid accelerating technology.

Even after recent failed drug trials, we think the company’s undervalued.

Seven of the top 10 dividend-yielding names are undervalued.

These three funds delivered in 2018 but had sizable outflows.

Several cases can be made for buying what seem to be fairly valued high-quality stocks.

At Aristotle, the emphasis is on long-term ownership.

Innovation, clearing regulatory picture, corporate restructurings, and capital redeployment should continue for healthcare stocks in the fourth quarter.

These wide-moat stocks with stable moat trends and low uncertainty ratings keep surprises to a minimum.

Innovation, consolidation, and a mixed regulatory picture for healthcare stocks in the second quarter.

We've lifted Hartford Equity Income's Morningstar Analyst Rating to Silver thanks to skipper Michael Reckmeyer's adept leadership.

New products in the pipeline can help the pharma firm continue to raise its payout.

This fund covers the entire overseas investable market.